General principles
Basic rule. A venoactive drug is an adjunct. It does not replace compression, it does not replace treatment of reflux, it does not replace anticoagulation. It acts on symptoms and oedema, not on the vein.
- Compression comes first. 20–30 mmHg in C2–C3, 30–40 mmHg in C4–C6. Before prescribing it, exclude an ABI < 0.80.
- Treatable reflux should be treated. With an ulcer and superficial reflux, early ablation improves healing and reduces recurrence. The drug covers the wait; it does not replace the procedure.
- Course and reassessment. 2–3 months, repeatable. If there is no subjective benefit after three months, stop rather than continue out of inertia.
- Check the current SmPC. This page summarises the evidence; it does not replace the package leaflet or the national reimbursement classification.
What the guidelines say
| Source | Content | Strength |
|---|---|---|
| ESVS 2022 — general recommendation | In patients with symptomatic chronic venous disease who are not candidates for intervention, are waiting for it, or have persistent symptoms after intervention, treatment with venoactive drugs should be considered on the basis of the evidence available for each individual drug. | Class IIa · Level A |
| ESVS 2022 — active venous ulcer | In addition to compression and local wound care: MPFF, oxerutins, pentoxifylline or sulodexide. | Class IIa · Level A |
| SVS / AVF / AVLS 2023 (varicose veins, Part II) | Venoactive drugs for symptomatic varicose veins in patients who are not candidates for intervention, are waiting for it, or have persistent symptoms: strength maintained, level of evidence varying from drug to drug. | Suggested |
| SIAPAV 2025 — Delphi consensus on venoactive nutraceuticals | Consensus on use across CEAP classes and on fixed-dose combinations as a first-line conservative option. No consensus on monotherapy with ruscus, horse chestnut, hydroxyethylrutosides, red vine leaf, anthocyanosides or β-arbutin. | Consensus |
Why this page grades drug by drug. The ESVS recommendation on venoactive drugs is single and generic for a very heterogeneous class: some drugs have robust RCTs, others poor-quality studies or effects similar to placebo. The point was raised publicly in a letter to the editor of EJVES in 2022. Treating "phlebotonics" as a single block is the mistake to avoid.
Oral drugs
| Active substance | Usual dose | Where the evidence is best | Quantitative data | Warnings |
|---|---|---|---|---|
| MPFF micronised purified flavonoid fraction (diosmin ~90% + hesperidin and other flavonoids ~10%) |
1000 mg/day (2 tablets of 500 mg or 1 sachet) |
Symptoms and oedema in all C classes; venous ulcer as an adjunct | Ulcer: healing at 6 months 61.3% vs 47.6%; RRR 32% (CI 3–70%); time to healing 16.1 vs 21.3 weeks | Mild gastrointestinal effects. Pregnancy and breastfeeding: limited data, avoid unless necessary |
| Hydroxyethylrutosides / oxerutins (troxerutin) | 1000 mg/day (up to 2000 mg/day for oedema) |
Symptoms and oedema; also cited by ESVS for ulcers | Reduction in ankle circumference vs placebo | GI effects, headache, rash |
| Ruscus aculeatus extract (often with hesperidin methyl chalcone and ascorbic acid) | according to formulation | Oedema | Among the venoactive drugs with the most RCTs on ankle circumference after MPFF | GI effects |
| Horse chestnut seed extract (aescin) | 100–150 mg aescin/day | Pain, oedema and itching in venous insufficiency | Cochrane 2012: 17 RCTs, 1581 participants; improvement in pain, oedema, leg volume and itching vs placebo; adverse events mild and infrequent | GI effects, dizziness, nausea, headache, itching |
| Calcium dobesilate | 1000–1500 mg/day (1000 = 1500 in efficacy) |
Night cramps and "discomfort"; greater effect in severe forms | Meta-analysis 2004, 10 RCTs, 778 patients: NNT 8 for cramps, NNT 4 for discomfort | Very rare agranulocytosis (estimated ~0.32 cases per million treated): stop it and check the blood count at any fever or sore throat. Reduce in severe renal failure on dialysis |
| Sulodexide glycosaminoglycan (80% heparan sulfate, 20% dermatan sulfate) |
250 LSU twice daily orally (600 LSU injectable formulation for initial courses) |
Venous ulcer; secondary prevention of VTE after stopping anticoagulation; post-thrombotic syndrome | SURVET (Circulation 2015, 615 patients with unprovoked VTE, 2 years): fewer recurrences without excess bleeding; meta-analysis RR 0.51 | Antithrombotic activity: caution or avoid in bleeding disorders, active bleeding, or in combination with anticoagulants or antiplatelet agents |
| Pentoxifylline | 400 mg three times daily (twice daily if poorly tolerated or with reduced renal function) |
Venous ulcer, as an adjunct to compression | Cochrane 2012, 12 RCTs, 864 patients: with compression RR 1.56 (CI 1.14–2.13); without compression RR 2.25 (CI 1.49–3.39). More adverse events: RR 1.56 (CI 1.10–2.22), 72% gastrointestinal | Contraindicated after extensive cerebral or retinal haemorrhage and in recent myocardial infarction; caution in hypotension, severe CKD, severe liver disease |
| Red vine leaf extract (Vitis vinifera) | 360–720 mg/day | Symptoms and mild oedema | Modest evidence | GI effects |
| Anthocyanosides, Centella asiatica, Melilotus | according to formulation | Symptoms | Weak and heterogeneous evidence | — |
| Coumarin (α-benzopyrone), benzarone | — | Do not use | — | Documented hepatotoxicity |
Diosmin products are not equivalent to one another. Micronisation, purity and composition differ, and guideline documents do not treat them as interchangeable. When prescribing for an ulcer, the evidence cited is that for the micronised purified fraction, not for any diosmin.
Varicose veins and symptomatic chronic venous disease (C0s–C2)
In practice
Basics. Compression 20–30 mmHg, exercise, weight control, avoiding prolonged standing, leg elevation in the evening.
Drug. Oral venoactive drug for heaviness, pain, cramps, restless legs and paraesthesiae. First choice on the strength of evidence: MPFF 1000 mg/day. Alternatives: oxerutins, ruscus, horse chestnut.
Course. 2–3 months, repeatable, often concentrated in the warm months when symptoms worsen.
Topical. Symptomatic relief, no effect on the disease.
When the drug is not enough. Symptomatic varicose veins with documented saphenous reflux: consider ablation or sclerotherapy. The drug covers the wait or residual symptoms.
Venous oedema (C3)
In practice
Basics. Compression 20–30 or 30–40 mmHg, elevation, calf-muscle exercise.
Drug. MPFF, hydroxyethylrutosides and Ruscus extract are the three with a proven reduction in ankle circumference. Calcium dobesilate in more severe forms.
No diuretics. Venous oedema is not fluid-overload oedema: a diuretic does not correct it, dehydrates the patient and may increase blood viscosity. It should be reserved for any coexisting systemic cause — heart failure, kidney disease, liver disease — which is a different diagnosis.
Before treating, always exclude non-venous causes of oedema: heart failure, hypoalbuminaemia, drugs (calcium-channel blockers, NSAIDs, gabapentinoids, corticosteroids), lymphoedema, DVT.
Skin changes (C4a / C4b)
In practice
Basics. Compression 30–40 mmHg and daily skin care with emollients.
Oral. MPFF; consider sulodexide or pentoxifylline in progressive lipodermatosclerosis, the precursor of ulceration.
Topical. Always an emollient or barrier cream. A moderate-potency topical corticosteroid for a short course (7–14 days) on varicose eczema — never on healthy skin, never on an ulcer bed.
Sensitisation. Allergic contact dermatitis is common in these patients (lanolin, fragrances, preservatives, topical antibiotics). Prefer simple, fragrance-free preparations.
Venous leg ulcer (C6) and healed ulcer (C5)
Non-negotiable standard: high-pressure multicomponent compression (≥ 40 mmHg at the ankle if the ABI allows) plus cleansing and a dressing suited to the wound bed and exudate. Everything else is adjunctive.
Pharmacological adjuncts
The four drugs cited by ESVS 2022 (Class IIa, Level A), to be added to compression:
| Drug | Regimen | Quantitative data |
|---|---|---|
| MPFF | 1000 mg/day for 6 months | Healing at 6 months 61.3% vs 47.6%; RRR 32% (CI 3–70%); time to healing 16.1 vs 21.3 weeks. Greater benefit for ulcers > 5 cm² and of 6–12 monthsduration; no benefit shown for ulcers of less than 6 months' duration |
| Pentoxifylline | 400 mg three times daily | Healing RR 1.56 (CI 1.14–2.13) in addition to compression; 2.25 (CI 1.49–3.39) when compression is not tolerated |
| Sulodexide | 250 LSU twice daily | Adjunct; particularly sensible when there is also a thrombotic risk |
| Oxerutins | 1000 mg/day | Cited by ESVS; more limited evidence than the first two |
Compression not tolerated or contraindicated (arterial disease, absolute intolerance): pentoxifylline is the only adjunct with favourable data even without compression. This is the situation in which it matters most.
Preventing recurrence (C5). Lifelong compression and treatment of superficial reflux. No drug has been shown to prevent recurrence.
Do not: use routine topical antibiotics (resistance and sensitisation); give systemic antibiotics without clinical signs of infection; replace compression with a drug.
Lymphoedema and oedema of lymphatic origin
There is no drug of proven efficacy on limb volume. The patient should be told this clearly: it is the area in which most is prescribed without evidence.
- Benzopyrones (coumarin, coumarin + troxerutin): the Cochrane review could not draw conclusions because of the poor quality of the studies; the most rigorous trial found no difference from placebo and reported a case of hepatotoxicity. Not recommended.
- Diuretics: not indicated. They remove water and leave the protein in the interstitium. Useful only if there is a coexisting systemic cause.
- Flavonoids: may improve symptoms in phlebolymphoedema (with an associated venous component), not the volume of pure lymphoedema.
What really works: complex decongestive therapy (manual lymphatic drainage, multilayer bandaging, exercise, skin care), then a maintenance compression garment; weight loss; early and aggressive treatment of erysipelas, with continuous antibiotic prophylaxis for recurrent cellulitis.
Always exclude: unrecognised secondary lymphoedema due to cancer, DVT, lipoedema, drug-induced oedema.
Superficial vein thrombosis (SVT)
SVT is not a condition for phlebotonics. It must be stratified with duplex ultrasound — distance from the junction, length of the segment — as in the site's
anticoagulant selector .
- Anticoagulant: fondaparinux 2.5 mg s.c. daily for 45 days is the option with the best evidence — RCT of 3002 patients: symptomatic VTE RR 0.15, extension RR 0.08, recurrence RR 0.21, without excess major bleeding. Alternatives: intermediate-dose LMWH for 45 days; rivaroxaban 10 mg daily.
- Oral NSAIDs: reduce extension and local recurrence but not symptomatic VTE. They do not replace the anticoagulant when one is indicated.
- Topical agents (heparin gel, MPS, diclofenac gel): relieve local symptoms; the Cochrane review reports no data on progression to VTE.
- Compression: yes, if tolerated.
A topical agent alone is not adequate treatment for SVT.
DVT and post-thrombotic syndrome
- Acute phase: anticoagulation according to the dedicated page (anticoagulant guidelines). Venoactive drugs have no role in the treatment of acute DVT.
- After stopping anticoagulation, in unprovoked VTE when the decision is not to continue: sulodexide reduced recurrences in the SURVET study with a favourable bleeding profile. It is an intermediate option between nothing and extended anticoagulation, to be discussed with the patient.
- Post-thrombotic syndrome: compression is the mainstay; MPFF and sulodexide have data on symptom improvement. No drug prevents PTS once established.
Topical agents and ointments
| Preparation | Reasonable use | What to expect | Notes |
|---|---|---|---|
| Sodium heparin gel (1000 IU/g) | Local symptoms of superficial phlebitis, bruising, after sclerotherapy | Symptomatic relief | No systemic anticoagulant effect |
| Mucopolysaccharide polysulfate (MPS) | As above | Symptomatic relief | — |
| Diclofenac gel | Pain and local inflammation in SVT | Reduction in pain and inflammation; in one RCT a favourable comparison against placebo and against heparin gel for local symptoms | Caution in NSAID allergy and NSAID-induced asthma; not on broken skin |
| Aescin + diethylamine salicylate gel | Bruising, post-traumatic oedema, local symptoms | Symptomatic relief | Not on broken skin; avoid in salicylate allergy |
| Hydroxyethylrutoside gel 2% | Heaviness, symptoms in C1–C3 | Symptomatic relief, cooling effect | — |
| Emollients and barrier creams | Always in C4–C6 | Reduce xerosis, itching and fissuring: real prevention of ulceration | Prefer fragrance-free and lanolin-free products |
| Topical corticosteroid | Varicose eczema, short course | Resolution of the eczematous phase | Never on the ulcer bed, never long term (atrophy) |
| Topical antibiotics | Essentially never | — | Resistance and contact sensitisation |
The SIAPAV 2025 consensus reports approval of topical agents across classes C1–C6, particularly for heaviness, while recognising the scarcity of good-quality evidence: they are safe and welcome adjuncts, not therapy.
Contraindications and special populations
| Situation | Practical consequence |
|---|---|
| Pregnancy and breastfeeding | Compression is the treatment of choice. Oral venoactive drugs: limited data, avoid unless necessary and in any case not in the first trimester. For antithrombotic prophylaxis see the dedicated page (LMWH; DOACs and VKAs excluded) |
| Severe renal impairment (eGFR < 30) or dialysis | Reduce calcium dobesilate; reduce or avoid pentoxifylline; review all doses |
| Severe liver disease | Avoid pentoxifylline; avoid coumarin and benzarone altogether |
| Ongoing anticoagulants or antiplatelet agents, bleeding disorders, recent bleeding | Caution with or avoid sulodexide; pentoxifylline contraindicated after extensive cerebral or retinal haemorrhage and in recent myocardial infarction |
| History of agranulocytosis or neutropenia | Avoid calcium dobesilate; if already being taken, stop it at every episode of fever or sore throat and check the blood count |
| NSAID allergy or NSAID-induced asthma | No diclofenac gel and no oral NSAIDs |
| ABI < 0.80 or known arterial disease | Compression reduced or contraindicated: this changes the whole strategy and, with an ulcer, increases the weight of oral adjuncts |
| Heart failure | The oedema is probably not (only) venous: reconsider the diagnosis before prescribing a venoactive drug |
| Active peptic ulcer, marked gastric intolerance | All oral venoactive drugs mainly cause gastrointestinal effects: reduce the dose, take with food, or switch to a topical agent |
Common errors
- Prescribing a venoactive drug instead of compression.
- Prescribing a venoactive drug instead of treating reflux in an ulcer with treatable superficial reflux.
- Using diuretics for venous oedema or lymphoedema.
- Treating SVT with topical gel alone.
- Using coumarin or benzarone.
- Topical or systemic antibiotics on an ulcer that is merely colonised.
- Continuing a venoactive drug for years without ever checking whether it is still needed.
- Treating all diosmin products as interchangeable.
Sources
- De Maeseneer MG et al. Editor's Choice — ESVS 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg 2022;63:184–267.
- Gloviczki P et al. SVS / AVF / AVLS clinical practice guidelines for the management of varicose veins of the lower extremities, Part II. J Vasc Surg Venous Lymphat Disord 2024.
- Letter to the editor on ESVS 2022, section 3.3 (pharmacological treatment). Eur J Vasc Endovasc Surg 2022.
- SIAPAV. Delphi Consensus on the Role of Venoactive Nutraceuticals in the Management of Chronic Venous Disease. Nutrients 2025;17(24):3830.
- Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg 2005;30:198–208.
- Jull AB, Arroll B, Parag V, Waters J. Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev 2012;12:CD001733.
- Andreozzi GM et al. Sulodexide for the prevention of recurrent venous thromboembolism (SURVET). Circulation 2015;132:1891–7.
- Di Nisio M, Wichers IM, Middeldorp S. Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev 2018;2:CD004982.
- Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev 2012;11:CD003230.
- Ciapponi A, Laffaire E, Roqué M. Calcium dobesilate for chronic venous insufficiency: a systematic review. Angiology 2004;55:147–54.
- Badger C, Preston N, Seers K, Mortimer P. Benzopyrones for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev 2004;2:CD003140.
- Allain H et al. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf 2004;27:649–60.
Disclaimer
A summary page for professional use. It does not replace the summary of product characteristics, the original guidelines or clinical judgement about the individual patient. Always check indications, dosage, contraindications and reimbursement in the current SmPC. Last content review: September 2026 (English version: November 2026).